MJFF Funds Continuing Analysis of Data from Phase 2 Trial of CERE-120
 

News flash from MJFF

MJFF Funds Continuing Analysis of Data from Phase 2 Trial of CERE-120

MJFF has signed on to fund the long-term, open-label analysis of data from Ceregene, Inc.’s Phase 2 trial of CERE-120, a gene therapy approach to deliver trophic factor neurturin to the brains of Parkinson’s patients. The funding will allow Ceregene to collect and analyze data from trial enrollees for another 48 months. While the study will be unblinded, the goal is to gather as much data on safety and efficacy as possible in an open-label study, while looking for suggestions of a longer-term neuroprotective effect.

“Our Foundation remains hopeful that neurotrophic factors can yield new and better treatments for PD,” said Katie Hood, MJFF CEO. “Extending the observation and analysis of Phase 2 trial enrollees represents a major opportunity to amass new data and learn from patients’ experience."

Read more at the MJFF Web site.